# Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED)

> **NCT00551876** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 214 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** MK0653, ezetimibe / Duration of Treatment: 30 Weeks
- **DRUG:** Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks

## Key facts

- **NCT ID:** NCT00551876
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-12
- **Primary completion:** 2003-01
- **Final completion:** 2003-01
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2024-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00551876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00551876, "Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00551876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*